Search Results
Your search for all items matches 35412 pages
Showing 11501 - 11550FDA Issues Emergency Use Authorization for First COVID-19 Test for Self-Testing at Home
On November 17, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the first COVID-19 diagnostic test for self-testing at home. The Lucira COVID-19 All-In-One Test Kit, which provides rapid results, is a molecular (real-time loop mediated amplification...
FDA Pipeline: Fast Track Designations in Liver and Pancreatic Cancers
Recently, the U.S. Food and Drug Administration (FDA) granted Fast Track designations to novel agents in the treatment of liver and pancreatic cancers. Fast Track Designation for SRF388 in Liver Cancer The FDA granted Fast Track designation to SRF388 for the treatment of patients with...
Paclitaxel Plus Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer: Long-Term Follow-up and Genomic Analysis
In a 7-year follow-up of the phase III CALGB 40601/Alliance neoadjuvant trial reported in the Journal of Clinical Oncology, Fernandez-Martinez et al found that paclitaxel combined with trastuzumab/lapatinib was associated with improved survival outcomes vs paclitaxel/trastuzumab in women with...
Addition of Irinotecan to Neoadjuvant Capecitabine Chemoradiation Guided by UGT1A1 Genotype in Locally Advanced Rectal Cancer
In a Chinese phase III trial reported in the Journal of Clinical Oncology, Zhu et al found that the addition of irinotecan to neoadjuvant capecitabine chemoradiation (CapIriRT)—with irinotecan dosing guided by UGT1A1 genotype—followed by capecitabine/irinotecan (XELIRI) significantly improved...
Sentinel Lymph Node Biopsy vs Lymphadenectomy for Staging of Intermediate- and High-Grade Endometrial Cancers
In a Canadian prospective cohort study (SENTOR) reported in JAMA Surgery, Cusimano et al found that sentinel lymph node biopsy showed “acceptable diagnostic accuracy” compared with lymphadenectomy in detecting nodal metastatic disease in patients with intermediate- and high-grade endometrial...
Cancer Deaths Linked to 4 Million Potential Years of Life Lost in 2017
Deaths from cancer accounted for more than 4 million potential years of life lost in 2017, according to a study published by Minkyo Song, MD, PhD, and colleagues in Cancer Epidemiology, Biomarkers & Prevention. While the cancer types with the highest death rates per capita accounted for the...
FDA Grants Accelerated Approval to Pembrolizumab for Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer
On November 13, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab (Keytruda) in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer whose tumors express PD-L1...
Immune-Related Adverse Events and Survival Outcomes in NSCLC
This week, we’re focusing on lung cancer—first, with a report on how therapy-related adverse events experienced by patients with lung cancer treated with immunotherapy may help to predict survival outcomes; and second, with a video about disparities in certain populations when it comes to lung...
Addition of Venetoclax to Bortezomib/Dexamethasone in Relapsed or Refractory Multiple Myeloma: BELLINI Trial
As reported in The Lancet Oncology by Shaji K. Kumar, MD, and colleagues, the phase III BELLINI trial has shown that the addition of venetoclax to bortezomib/dexamethasone significantly prolonged progression-free survival in patients with relapsed or refractory multiple myeloma but was associated...
Virtual Mind-Body Services for Patients With Cancer During the COVID-19 Pandemic
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Jun J. Mao, MD, MSCE, and Jyothirmai Gubili, MS, focus on the role of virtual...
Survey Finds Patients With Cancer May Be Less Likely to Enroll in Clinical Trials During the COVID-19 Pandemic
A portion of patients with cancer may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic. According to a report published as a research letter by Mark E. Fleury, PhD, and colleagues in JAMA Oncology, nearly one in five patients with cancer surveyed said the...
Ivosidenib Plus Azacitidine in Newly Diagnosed IDH1-Mutant Acute Myeloid Leukemia
In a phase Ib study reported in the Journal of Clinical Oncology, Courtney D. DiNardo, MD, and colleagues found that the combination of ivosidenib and azacitidine produced a high response rate in patients with newly diagnosed isocitrate dehydrogenase 1 (IDH1)-mutant acute myeloid leukemia...
Can Circulating Tumor Cell Count Guide First-Line Chemotherapy or Endocrine Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer?
In the French phase III STIC CTC trial reported in JAMA Oncology, François-Clément Bidard, MD, PhD, and colleagues found that choice of first-line chemotherapy vs endocrine therapy in hormone receptor (HR)-positive, HER2-negative metastatic breast cancer based on circulating tumor cell count...
Is Maintenance Treatment With Olaparib for BRCA-Mutated Pancreatic Cancer Cost-Effective?
Studies have shown that utilizing a PARP inhibitor in the management of patients with metastatic pancreatic cancer and BRCA1/2 mutation is clinically beneficial. New research published by Wu et al in JNCCN—Journal of the National Comprehensive Cancer Network sought to determine whether such...
Meta-analysis of Outcomes With Gamma Knife Radiosurgery for Uveal Melanoma or Ocular Metastases
In a systematic review and meta-analysis reported in The Lancet Oncology, Parker et al found that Gamma Knife radiosurgery was associated with high local control and tumor regression rates in patients with uveal melanoma or intraocular metastases. As stated by the investigators, “Gamma [K]nife...
Adjuvant Irinotecan/Cisplatin vs Etoposide/Cisplatin for Resected High-Grade Neuroendocrine Carcinoma of the Lung
In a Japanese phase III trial reported in the Journal of Clinical Oncology, Kenmotsu et al found that adjuvant irinotecan/cisplatin did not improve relapse-free survival vs etoposide/cisplatin in patients with completely resected, pathologic stage I–IIIA, high-grade neuroendocrine carcinoma of the...
Surgical Technical Skill and Long-Term Survival After Surgery for Colon Cancer
In a study reported as a research letter in JAMA Oncology, Brajcich et al found that higher-rated surgical technical skill was associated with significantly improved long-term survival in patients undergoing surgery for colon cancer. Study Details In the study, surgeons were recruited from the...
Expert Point of View: William R. Sellers, MD
William R. Sellers, MD, Professor of Medicine at Harvard Medical School and the Dana-Farber Cancer Institute and Co-Chair of the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer, commented: “This study is a good example of how our increasing ability to study the human genome easily and in...
Genetic Variants Linked to Bevacizumab-Induced Adverse Effects
Two common genetic variants appear to be linked to toxicity induced by bevacizumab, researchers reported at the 32nd European Organisation for Research and Treatment of Cancer (EORTC)–National Cancer Institute (NCI)–American Association for Cancer Research (AACR) Symposium on Molecular Targets and...
Mary Pasquinelli, DNP, APRN, FNP-BC, on Addressing Lung Cancer Care Equity in Vulnerable Communities
Mary Pasquinelli, DNP, APRN, FNP-BC, of the University of Illinois Hospital and Health Science System, discusses proposed U.S. Preventive Services Task Force lung cancer screening guidelines, which show race and gender disparities, and how modifying these recommendations with a risk prediction...
Expert Point of View: Therese Marie Mulvey, MD, FASCO
Therese Marie Mulvey, MD, FASCO, Director of Quality Safety and Value at the Massachusetts General Hospital North Shore Cancer Center, Boston, told The ASCO Post that this “provocative and elegant” study underscores the importance of listening to patients. “Baseline patient-reported symptoms are...
Ask Patients With Advanced Cancer About Fatigue: The Answer May Reveal Survival Odds
Fatigue could be an important baseline stratification factor for cancer treatment, according to data presented during the 2020 ASCO Quality Care Symposium.1 An analysis of four SWOG treatment trials has found an association between patient fatigue and outcomes in advanced cancer. Data from the...
Study Finds State-Level Lung Cancer Screening Rates Not Aligned With Lung Cancer Burden in the United States
A new study published by Stacey A. Fedewa, PhD, and colleagues in JNCI: Journal of the National Cancer Institute found that state-level lung cancer screening rates were not aligned with the national lung cancer burden. The report provides the first population-based state-level screening data for...
Addition of Indoximod to Taxane Chemotherapy in First-Line Treatment of HER2-Negative Metastatic Breast Cancer
In a phase II trial reported in JAMA Oncology, Mariotti et al found that the addition of the indoleamine 2,3-dioxygenase 1 (IDO1) pathway inhibitor indoximod to a taxane did not improve progression-free survival in first-line treatment of patients with metastatic HER2-negative breast cancer. As...
Comanagement of Induction Therapy for Acute Promyelocytic Leukemia by Experts and Community Practices
In a study reported in JCO Oncology Practice, Anand P. Jillella, MD, and colleagues found that physician education on the main causes of death during induction treatment for acute promyelocytic leukemia (APL)—and comanagement of cases with expert physicians—resulted in a low early mortality rate...
Serial COVID-19 Screening in Asymptomatic Patients Receiving Treatment for Cancer
In a United Arab Emirates single-institution study reported as a research letter in JAMA Oncology, Al-Shamsi et al found a high rate of COVID-19 infection among asymptomatic patients with solid tumors undergoing cancer treatment. Study Details The study included 109 patients receiving treatment for ...
Closing the Gap in Integrative Oncology Education
Launched in 2018 at the University of Michigan Medical School in Ann Arbor, the Integrative Oncology Scholars Program has trained 50 oncology professionals in evidence-based complementary therapies in the treatment of patients with cancer. Another 50 trainees are expected to complete the program by ...
James L. Mulshine, MD, on Meeting Highlights: Advancing Quantitative Low-Dose CT Imaging in Thoracic Disease
James L. Mulshine, MD, of Rush University Medical Center, offers an overview of the 2020 Quantitative Imaging Workshop, whose mission is to leverage the use of CT to speed early detection and improve the management of lung cancer and other thoracic diseases.
Medicaid Expansion Associated With Decreased Mortality in Patients With Newly Diagnosed Breast, Colorectal, and Lung Cancers
In states that have expanded Medicaid availability as part of the Affordable Care Act (ACA), mortality rates for three major types of cancer are significantly lower than in states that have not expanded their Medicaid, according to findings from a new study published by Miranda B. Lam, MD, MBA, and ...
Reduced Breast Cancer Mortality and Risk of Recurrence With Internal Mammary and Medial Supraclavicular Nodal Irradiation in Stage I to III Breast Cancer
As reported in The Lancet Oncology by Philip M. Poortmans, PhD, and colleagues, 15-year outcomes of the phase III EORTC 22922/10925 trial show continued reductions in both breast cancer mortality and recurrence with postsurgery internal mammary and medial supraclavicular (IM-MS) lymph node chain...
rhG-CSF and Decitabine to Reduce Risk of Relapse in Patients With AML After Stem Cell Transplant
In a Chinese phase II trial reported in the Journal of Clinical Oncology, Gao et al found that prophylactic recombinant human granulocyte colony-stimulating factor (rhG-CSF) and minimal-dose decitabine reduced the risk of relapse vs no intervention among patients with high-risk, minimal residual...
Risk of Metachronous Contralateral Testicular Cancer According to Platinum-Based Chemotherapy Exposure
In a Dutch study reported in the Journal of Clinical Oncology, Blok et al found a significant association between an increased number of cycles of platinum-based chemotherapy and a reduced risk of metachronous contralateral testicular cancer. As noted by the investigators, patients with testicular...
Rising Tide Foundation for Clinical Cancer Research Career Pathway Grants in Symptom Management
Conquer Cancer, the ASCO Foundation® announced the 2020 recipients of the Conquer Cancer–Rising Tide Foundation for Clinical Cancer Research Career Pathway Grants in Symptom Management. The Career Pathway Grants in Symptom Management are awarded to recruit and retain young physician-scientists...
Project N95 Partnership Provided ASCO Members With Access to Personal Protective Equipment
The COVID-19 pandemic has made 2020 a challenging year for everyone, including cancer care providers, many of whom have had difficulty obtaining personal protective equipment (PPE) for their patients and staff during the pandemic. To help ease this burden on its members, ASCO partnered with Project ...
Hospital Outpatient Payment Proposal Has Potential to Undermine Patient Access to Cancer Care
In a comment letter to the Centers for Medicare & Medicaid Services (CMS), the Association for Clinical Oncology (ASCO) expressed significant concerns that provisions in the 2021 Hospital Outpatient Prospective Payment System (HOPPS) proposed rule have the potential to undermine access to...
Your Stories: ‘Being Your Own Advocate’
Kimberly Irvine was used to taking care of the people she loved. Conquering breast cancer—twice—forced the young mom to learn how to take care of herself in a whole new way. In the Your Stories episode “Being Your Own Advocate,” she shares with fellow philanthropist Riccardo Braglia, Board Member, ...
Support Caregivers During National Family Caregivers Month With ASCO Answers
Cancer.Net provides a variety of tools and resources for caregivers, including the ASCO Answers Guide to Caregiving. This guide includes: Practical tips for supporting a patient with cancer Advice for talking with family and the health-care team Convenient symptom and medication trackers And...
COVID-19’s Impact on Cancer Care Around the World: Perspectives From the ASCO International Affairs Committee
As the world continues to respond to the COVID-19 pandemic, ASCO is committed to providing the most current information and resources to its members and the larger oncology community to help ensure that patients with cancer receive high-quality care. Here, members of the ASCO International Affairs...
Inaugural Class of FDA-AACR Oncology Educational Fellows Announced
The American Association for Cancer Research (AACR) has announced the 2020–2021 class of U.S. Food and Drug Administration (FDA)-AACR Oncology Educational Fellows. This is the first year of the fellowship, a joint initiative of the Oncology Center of Excellence at the FDA and the AACR. The...
Stereo X-Ray of Stomach Cancer
The text and photograph here are excerpted from a four-volume series of books titled Oncology: Tumors & Treatment, A Photographic History, The X-Ray Era 1901–1915 by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. Photograph courtesy of Stanley B. Burns, MD, and The Burns Archive. A few...
My Age May Have Been a Barrier to Timely Diagnosis of Glioblastoma Multiforme
I think my age and apparent good health contributed to a delay in my diagnosis of glioblastoma multiforme. The first symptom I had of the cancer appeared on December 26, 2014, when I was 32 years old. My family and I had just gotten home from celebrating the Christmas holiday with our relatives...
Michaela A. Dinan, PhD, Named Co-Leader of Cancer Prevention and Control Research Program at Yale
Michaela A. Dinan, PhD, has been appointed Co-Leader of the Cancer Prevention and Control Research Program at Yale Cancer Center, beginning January 1, 2021. Dr. Dinan was also named Associate Professor in the Department of Chronic Disease Epidemiology at the Yale School of Public Health and will...
Combination of Nivolumab and Ipilimumab for Unresectable Malignant Pleural Mesothelioma
On October 2, 2020, the combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) was approved for first-line treatment of adult patients with unresectable malignant pleural mesothelioma.1-3 Supporting Efficacy Data Approval was based on findings in the open-label phase III CheckMate 743 trial...
Beyond BROCADE3: Just the Beginning for Veliparib-Based Therapy in Advanced BRCA-Mutated Breast Cancer
As recently reported in The Lancet Oncology and reviewed in the October 10, 2020, issue of The ASCO Post, the phase III BROCADE3 trial has shown that the addition of veliparib to carboplatin and paclitaxel improved progression-free survival in previously treated BRCA-mutated advanced breast...
DANUBE Trial Reports No Survival Benefit With First-Line Durvalumab in Metastatic Urothelial Carcinoma
As reported in The Lancet Oncology by Thomas Powles, MD, of Barts Cancer Institute, Queen Mary University of London, and colleagues, the phase III DANUBE trial showed that durvalumab monotherapy did not prolong overall survival vs standard chemotherapy in previously untreated patients with...
Expert Point of View: Kilian M. Gust, MD
Formal discussant Kilian M. Gust, MD, of the Medical University of Austria, Vienna, reminded listeners that JAVELIN Bladder 100 was designed at a time when no checkpoint inhibitor was approved for the treatment of metastatic urothelial cancer. In the past 5 years, five immune checkpoint inhibitors...
A Doctor Shares His Rich Life in Medicine and Cancer Research
“What am I doing here? This question kept running through my mind as the incoming freshman medical students at the University of Chicago assembled for the first time.” The person asking the introspective question was Marvin Stone, fresh out of college, recently married to his wife, Jill, and now a...
Front-Line Avelumab Maintenance Improved Survival Across Subgroups With Advanced Urothelial Carcinoma
A strategy of front-line maintenance treatment with the PD-L1 inhibitor avelumab combined with best supportive care improved both progression-free and overall survival vs best supportive care alone across prespecified subgroups of patients with advanced or metastatic urothelial carcinoma that had...
An Emergency Room Physician Explores Her Own Healing Through a Life of Medical Service
Medical memoir dramas, especially those centered in the emergency room (ER), are often met with the anticipation of top-rated medical shows portrayed on TV, in which there is nonstop blood-and-guts action and sizzling tensions between shouting doctors and nurses. In her recently published memoir,...
Three New Transatlantic Research Teams to Study Difficult-to-Treat Childhood Cancers
Although remarkable progress has been made in advancing pediatric cancer research, critical unmet needs remain, especially for more aggressive cancers such as neuroblastomas and Ewing sarcoma. The Stand Up To Cancer–Cancer Research UK Pediatric Cancer New Discoveries Challenge has awarded three...
